The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics
Open accessAbstract
BACKGROUND AND OBJECTIVE: A large interindividual variability exists in the plasma concentrations of repaglinide. Our aim was to investigate possible associations between the pharmacokinetics of repaglinide and single nucleotide polymorphisms (SNPs) in the genes encoding for the drug transporters organic anion transporting polypeptide 1B1 (OATP1B1) (SLCO1B1 ) and P-glycoprotein ( MDR1 , ABCB1 ) and the drug-metabolizing enzymes cytochrome P450 (CYP) 2C8 and CYP3A5. METHODS: A total of 56 healthy volunteers ingested a single 0.25-mg dose of repaglinide. Plasma repaglinide and blood glucose concentrations were measured for up to 7 hours. All subjects were genotyped for the -11187G>A and 521T>C SNPs in SLCO1B1 and the 3435C>T and 2677G>T/A SNPs in ABCB1 , as well as for the CYP2C8*3 (416G>A, 1196A>G), CYP2C8*4 (792C>G), and CYP3A5*3 (6986A>G) alleles. RESULTS: The area under the plasma concentration-time curve from time 0 to infinity [AUC(0-infinity)] and peak concentration in plasma (Cmax) of repaglinide varied 16.9-fold and 10.7-fold, respectively, between individual subjects. Multiple regression analyses indicated that the SLCO1B1 521T>C SNP and the CYP2C8*3 allele were independent predictors of the AUC(0-infinity) and Cmax of repaglinide (adjusted multiple R2 = 45% and 36%, respectively). In subjects with the SLCO1B1 521CC genotype, the AUC(0-infinity) of repaglinide was 107% and 188% higher, respectively, than in subjects with the SLCO1B1 521TC or 521TT (reference) genotype (P < .0001). In subjects with the CYP2C8*1/*3 genotype, the AUC(0-infinity) and Cmax of repaglinide were 48% and 44% lower, respectively, than in those with the CYP2C8*1/*1 genotype (P < .05). The pharmacokinetics of repaglinide was not associated with the studied ABCB1 SNPs or the CYP3A5*3 allele. The elimination half-life of repaglinide was not associated with any SNP. Only the SLCO1B1 -11187GA genotype was significantly associated with an enhanced effect of repaglinide on blood glucose. CONCLUSIONS: Genetic polymorphism in SLCO1B1 is a major determinant of interindividual variability in the pharmacokinetics of repaglinide. The effect of SLCO1B1 polymorphism on the pharmacokinetics of repaglinide may be clinically important.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
Self-citationHagenbuch, B., & Meier, P. J. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1168-y · Cited by 1,019
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
Marzolini, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.012 · Cited by 895
Tirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 626
Importance of P-glycoprotein at blood–tissue barriers
Fromm, M. F. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.06.002 · Cited by 592
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
Dai, D., Zeldin, D. C., Blaisdell, J. A., Chanas, B., Coulter, S. J., Ghanayem, B. I., & Goldstein, J. A. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00006 · Cited by 494
Niemi, M., Schaeffeler, E., Lang, T., Fromm, M. F., Neuvonen, M., Kyrklund, C., Backman, J. T., Kerb, R., Schwab, M., Neuvonen, P. J., et al. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114750.08559.32 · Cited by 418
Self-citationGorski, J. C., Jones, D. R., Haehner-Daniels, B. D., Hamman, M. A., O'Mara, E. M., & Hall, S. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90146-1 · Cited by 411
Olkkola, K. T., Backman, J. T., & Neuvonen, P. J. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.60 · Cited by 409
Self-citationShitara, Y., Hirano, M., Sato, H., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068536 · Cited by 407
Shitara, Y., Itoh, T., Sato, H., Li, A. P., & Sugiyama, Y. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041921 · Cited by 340
SIMONSON, S. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.010 · Cited by 330
Genetic Polymorphisms of the Human MDR1 Drug Transporter
Schwab, M., Eichelbaum, M., & Fromm, M. F. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140233 · Cited by 308
Self-citationModulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene
Johne, A., Köpke, K., Gerloff, T., Mai, I., Rietbrock, S., Meisel, C., Hoffmeyer, S., Kerb, R., Fromm, M. F., Brinkmann, U., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129196 · Cited by 306
Self-citationEvidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
Mwinyi, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.016 · Cited by 293
Niemi, M., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2003) · Diabetologia · doi:10.1007/s00125-003-1034-7 · Cited by 284
Self-citationFrequency of C3435T polymorphism of MDR1 gene in African people
Schaeffeler, E., Eichelbaum, M. F., Brinkmann, U., Penger, A., Asante-Poku, S., Zanger, U. M., & Schwab, M. G. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05579-9 · Cited by 281
Self-citationBahadur, N., Leathart, J. B. S., Mutch, E., Steimel-Crespi, D., Dunn, S. A., Gilissen, R., Houdt, J. V., Hendrickx, J., Mannens, G., Bohets, H., et al. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01354-0 · Cited by 235
Self-citationInteraction of Common Azole Antifungals with P Glycoprotein
Wang, E.-J., Lew, K., Casciano, C. N., Clement, R. P., & Johnson, W. W. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.160-165.2002 · Cited by 233
Clinical Pharmacokinetics of Pravastatin: Mechanisms of Pharmacokinetic Events
Hatanaka, T. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039060-00002 · Cited by 224
Bidstrup, T. B., Bjørnsdottir, I., Sidelmann, U. G., Thomsen, M. S., & Hansen, K. T. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2003.01862.x · Cited by 209
Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein*
Wakasugi, H., Yano, I., Ito, T., Hashida, T., Futami, T., Nohara, R., Sasayama, S., & Inui, K.-I. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90030-3 · Cited by 200
Pharmacogenetics of the major polymorphic metabolizing enzymes
Daly, A. K. (2003) · Fundamental & Clinical Pharmacology · doi:10.1046/j.1472-8206.2003.00119.x · Cited by 189
Self-citationGemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes
Wang, J.-S., Neuvonen, M., Wen, X., Backman, J. T., & Neuvonen, P. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1352 · Cited by 189
Self-citationGARCIAMARTIN, E. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.006 · Cited by 182
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide
Niemi, M. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00228-5 · Cited by 181
Self-citationFuruno, T., Landi, M.-T., Ceroni, M., Caporaso, N., Bernucci, I., Nappi, G., Martignoni, E., Schaeffeler, E., Eichelbaum, M., Schwab, M., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200210000-00004 · Cited by 178
Self-citationEVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM
Huang, W., Lin, Y. S., McConn, D. J., Calamia, J. C., Totah, R. A., Isoherranen, N., Glodowski, M., & Thummel, K. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001313 · Cited by 175
Clinical Pharmacokinetics and Pharmacodynamics of Repaglinide
Hatorp, V. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241070-00002 · Cited by 151
Niemi, M., Neuvonen, P. J., & Kivistö, K. T. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116511 · Cited by 113
Self-citationNiemi, M., Kajosaari, L. I., Neuvonen, M., Backman, J. T., & Neuvonen, P. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02027.x · Cited by 97
Self-citationGenomic evidence for recent positive selection at the human MDR1 gene locus
Tang, K., Wong, L.-P., Lee, E. J. D., Chong, S. S., & Lee, C. G. L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh099 · Cited by 95
Hedman, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.011 · Cited by 93
van Heiningen, P. N. M., Hatorp, V., Nielsen, K. K., Hansen, K. T., van Lier, J. J., van de Merbel, N. C., Oosterhuis, B., & Jonkman, J. H. G. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050667 · Cited by 83
CYP3A5 phenotype‐genotype correlations in a British population
King, B. P., Leathart, J. B. S., Mutch, E., Williams, F. M., & Daly, A. K. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01798.x · Cited by 75
Self-citationHatorp, V., Oliver, S. D., & Su, C. A. (1998) · PubMed · Cited by 63
Kajosaari, L. I., Backman, J. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02158.x · Cited by 37
Self-citation
Cited by
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Self-citationSLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Ingelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Impact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
Self-citationDrug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Self-citation
Metadata
- Authors
- NIEMI, M., BACKMAN, J., KAJOSAARI, L., LEATHART, J., NEUVONEN, M., DALY, A., EICHELBAUM, M., KIVISTO, K., & NEUVONEN, P.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2005-06
- Volume
- 77
- Issue
- 6
- Pages
- 468-478
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2153372327
- Cited by
- 360
- References
- 38
- FWCI
- 23.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.